Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Reasons for Emergency Use Authorization of Tamiflu and Relenza

Content on this page was developed during the 2009-2010 H1N1 pandemic and has not been updated.

  • The H1N1 virus that caused that pandemic is now a regular human flu virus and continues to circulate seasonally worldwide.
  • The English language content on this website is being archived for historic and reference purposes only.
  • For current, updated information on seasonal flu, including information about H1N1, see the CDC Seasonal Flu website.

April 29, 2009, 1:45 AM ET

Tamiflu and Relenza are both FDA-approved antiviral drugs that fight against the current swine influenza A (H1N1) virus.

Tamiflu is FDA-approved to treat and prevent influenza in people one year of age and older.  Relenza is FDA-approved for treatment of influenza in people 7 years and older and for prevention of influenza in people 5 years and older.

A Public Health Emergency has been declared due to the outbreak of swine influenza A (H1N1) infections identified in the United States and abroad.

During an emergency, normal prescribing and dispensing requirements may not be met for Tamiflu and Relenza.  Therefore, the Commissioner of the Food and Drug Administration (FDA) has authorized the emergency use of Tamiflu under an Emergency Use Authorization (EUA) for the following reasons:

  1. To allow for dispensing of these antiviral drugs to patients without all of the FDA-required information on typical prescription labels (e.g. patient’s name, doctor’s name, and date of dispensing),
  2. to allow for designated public health officials to distribute antiviral drugs during an emergency when there are shortages of doctors, nurses, and pharmacists,
  3. to allow for distribution of antiviral drugs that have had the original manufacturer’s expiration dating extended by FDA, and
  4. to be able to treat and prevent swine influenza A in infants and children younger than the FDA-approved ages (less than 1 year of age for Tamiflu).

An EUA is necessary for Relenza for reasons 1 and 2 listed above.

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #